AAPL 203.88 +0.14 (+0.07%)MSFT 123.45 +0.4 (+0.33%)FB 178.27 +0.03 (+0.02%)ZNGA 5.44 +0.09 (+1.59%)NVDA 186.25 +0.19 (+0.10%)WBA 54.62 -0.33 (-0.60%)GOOG 1237.48 -0.16 (-0.01%)PIH 5.25 -0.05 (-0.94%)
AAPL 203.88 +0.14 (+0.07%)MSFT 123.45 +0.4 (+0.33%)FB 178.27 +0.03 (+0.02%)ZNGA 5.44 +0.09 (+1.59%)NVDA 186.25 +0.19 (+0.10%)WBA 54.62 -0.33 (-0.60%)GOOG 1237.48 -0.16 (-0.01%)PIH 5.25 -0.05 (-0.94%)

Cash Flow ADAP Quote Adaptimmune

All | Income Statement | Balance Sheet | Cash Flow | Retained Earnings | PPE Schedule | Intangible and Goodwill Schedule
Year 201420152016
NetIncome -22 -72 -70
Depreciation 1 3 5
DeferredIncomeT 0 0 0
StockBasedCompe 4 9 11
AccountsReceiva 0 0 0
InventoryCS 0 0 0
AccountsPayable 0 0 0
OtherWorkingCap -14 12 7
OtherNonCashIte -24 -1 -8
NetCashProvided -33 -48 -54
InvestmentsInPP -5 -12 -25
AcquisitionsNet 0 0 0
PurchasesOfInve -55 0 -153
SalesMaturities 0 0 29
PurchasesOfInta 0 -1 0
OtherInvestingA 0 31 23
NetCashUsedForI -60 18 -126
DebtIssued 0 0 0
DebtRepayment 0 0 0
CommonStockIssu 275 0 103
CommonStockRepu 0 0 0
DividendPaid 0 0 0
OtherFinancingA 0 0 0
NetCashProvided 275 0 104
NetChangeInCash 182 -36 -74
CashAtBeginning 47 199 163
CashAtEndOfPeri 229 163 88
Adaptimmune Therapeutics plc income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Adaptimmune Therapeutics plc FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.